Örebro University Hospital is a university hospital in Örebro, Sweden. The hospital is operated by Örebro County Council and took its current name in 2000, having previously been called Örebro Regional Hospital.

There are 462 (2015-02-06) beds in Universitetssjukhuset Örebro.

During the past decade, Universitetssjukhuset Örebro conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 4 clinical trials were completed, i.e. on average, 11.8% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 3 clinical trials were completed. i.e. 15.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitetssjukhuset Örebro" #1 sponsor was "Pfizer" with 6 trials, followed by "Advanz Pharma" with 3 trials sponsored, "Bayer" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored and "Karolinska University Hospital" with 3 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitetssjukhuset Örebro" #1 collaborator was "Uppsala University Hospital" with 3 trials as a collaborator, "Haukeland University Hospital" with 2 trials as a collaborator, "Helse Stavanger HF" with 2 trials as a collaborator, "Karolinska University Hospital" with 2 trials as a collaborator and "Odense University Hospital" with 2 trials as a collaborator. Other collaborators include 71 different institutions and companies that were collaborators in the rest 78 trials.

According to Clinical.Site data, the most researched conditions in "Universitetssjukhuset Örebro" are "Atrial Fibrillation" (5 trials), "Multiple Myeloma" (4 trials), "Coronary Artery Disease" (2 trials), "Crohn Disease" (2 trials) and "Myocardial Infarction" (2 trials). Many other conditions were trialed in "Universitetssjukhuset Örebro" in a lesser frequency.

Most popular intervention types in "Universitetssjukhuset Örebro" are "Drug" (30 trials), "Other" (11 trials), "Device" (8 trials), "Biological" (5 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Daratumumab" (3 trials), "Dexamethasone" (3 trials), "Atezolizumab" (2 trials) and "Elranatamab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universitetssjukhuset Örebro" are 50 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Universitetssjukhuset Örebro". undefined are not yet recruiting, 20 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Universitetssjukhuset Örebro, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Universitetssjukhuset Örebro, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 9 trials that are defined as “Not Applicable".